Oferta Our offer
PL EN

Tuberculosis

BACTEC MGIT 960 – Drug Susceptibility Testing for Second-Line Anti-Tuberculosis Drugs
Czas oczekiwania: Culture (4 to 42 days) plus an additional 4 to 21 days Waiting time: Culture (4 to 42 days) plus an additional 4 to 21 days

When should the test be performed?
BACTEC MGIT 960 is a qualitative method for assessing the susceptibility of Mycobacterium tuberculosis to additional anti-tuberculosis drugs used in the treatment of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) tuberculosis. Indications for performing the test include:

  • Suspected MDR-TB or XDR-TB
  • Confirmed M. tuberculosis infection with resistance to first-line drugs
  • Monitoring the effectiveness of anti-TB treatment
  • Epidemiological studies on M. tuberculosis drug resistance

Test description
The BACTEC MGIT 960 system enables the assessment of mycobacterial growth in the presence of critical concentrations of selected second-line drugs, including:

  • Amikacin
  • Ofloxacin
  • Capreomycin
  • Kanamycin
  • Moxifloxacin

The BACTEC MGIT 960 system automatically monitors bacterial growth and analyzes susceptibility to the tested antibiotics. This method provides accurate results in a shorter time compared to traditional phenotypic methods. Automated growth detection eliminates subjective interpretation and ensures high diagnostic reliability.

Diagnostic significance
The BACTEC MGIT 960 test for second-line anti-TB drugs is a crucial tool in the diagnosis and management of multidrug-resistant tuberculosis. Early detection of resistance to second-line medications allows for timely implementation of appropriate treatment regimens, which is essential for improving therapeutic outcomes and limiting the transmission of resistant strains.

Test results
Results are available electronically or for in-person collection. The Center for Clinical Medicine provides comprehensive tuberculosis diagnostics, utilizing advanced drug susceptibility testing methods and offering expert support in anti-TB therapy management.

kontakt@dimedical.pl
+48 502 660 480